Treatment with MitraClip has shown clinically meaningful changes to quality of life, a reduction in rehospitalisation for heart failure, and functional improvements for patients with degenerative mitral regurgitation who are at prohibitive risk for mitral valve surgery, it states in a company press release.
The findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco (27 October–1 November) and simultaneously published in the Journal of the American College of Cardiology.
The MitraClip device, which received US Food and Drug Administration (FDA) approval last week, provides physicians with a breakthrough treatment option for patients suffering from mitral regurgitation. The MitraClip device is now available in the USA for patients with significant symptomatic degenerative mitral regurgitation who are at prohibitive risk for mitral valve surgery.
“The results of this study show that, even for some of the most ill and debilitated patients, the MitraClip system is safe and results in good clinical outcomes,” said D Scott Lim, associate professor of Cardiovascular Medicine at the University of Virginia Health System in Charlottesville, USA, and lead author of the publication. “These prohibitive-risk patients have had, until now, no approved therapies to improve the quality of their lives.”
Data from 127 patients with degenerative mitral regurgitation at prohibitive surgical risk treated with the MitraClip device demonstrate:
- Clinically meaningful changes to quality of life. Following MitraClip treatment, changes in SF-36 summary scales (a quality-of-life survey) were well above established thresholds showing minimum clinically important differences
- A reduction in rehospitalisation for heart failure of 73%
- Functional improvements, with 76% of patients with baseline NYHA Functional Class III improving to NYHA Functional Class I or II, and 65% of patients with baseline NYHA Functional Class IV improving to NYHA Functional Class I or II
- Favourable ventricular remodelling, with left ventricular end-diastolic and end-systolic volume decreased significantly at one year compared with baseline
- A majority of patients discharged to home (87%), rather than to nursing care.
The data were presented during the TCT conference by Ted Feldman, director, Cardiac Catheterization Laboratory and The Mr and Mrs Charles R Walgreen Chair in Interventional Cardiology, NorthShore University HealthSystem, Evanston, USA.
“These positive results, which were reviewed as part of the totality of data from Abbott’s FDA submission, along with clinical results from more than 2,200 patients treated with the device, confirm the benefit of the innovative MitraClip therapy for this very sick patient population,” said Chuck Foltz, senior vice president, vascular, Abbott. “This year’s TCT conference has been particularly exciting for Abbott, with enormous enthusiasm about MitraClip from clinicians in the USA and around the world, and more than 65 presentations highlighting data related to the therapy.”